Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Director Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $53.55, for a total value of $160,650.00. Following the sale, the director now directly owns 12,939 shares in the company, valued at $692,883.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Joseph Klein III also recently made the following trade(s):

  • On Wednesday, November 15th, Joseph Klein III sold 2,250 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $53.56, for a total value of $120,510.00.
  • On Monday, November 13th, Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $55.39, for a total value of $166,170.00.

Ionis Pharmaceuticals, Inc. (IONS) opened at $56.93 on Monday. The company has a quick ratio of 6.21, a current ratio of 6.25 and a debt-to-equity ratio of 1.50. Ionis Pharmaceuticals, Inc. has a 52 week low of $37.26 and a 52 week high of $65.51. The company has a market capitalization of $7,104.61, a P/E ratio of 379.53 and a beta of 2.85.

A number of analysts have recently issued reports on IONS shares. Goldman Sachs Group reaffirmed a “sell” rating and set a $30.00 target price on shares of Ionis Pharmaceuticals in a research report on Friday, October 6th. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $62.00 price target for the company in a research note on Friday, October 27th. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price target on shares of Ionis Pharmaceuticals in a research note on Sunday, September 17th. Barclays started coverage on Ionis Pharmaceuticals in a research note on Wednesday, September 6th. They issued an “equal weight” rating and a $55.00 price target for the company. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $50.00 price target on shares of Ionis Pharmaceuticals in a research note on Friday, October 13th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company’s stock. Ionis Pharmaceuticals currently has an average rating of “Hold” and an average price target of $50.31.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Ionis Pharmaceuticals by 4.4% during the second quarter. Vanguard Group Inc. now owns 9,855,160 shares of the company’s stock worth $501,332,000 after buying an additional 417,364 shares during the period. BlackRock Inc. boosted its position in shares of Ionis Pharmaceuticals by 4.0% during the second quarter. BlackRock Inc. now owns 6,823,987 shares of the company’s stock worth $347,135,000 after buying an additional 264,179 shares during the period. American Century Companies Inc. boosted its position in shares of Ionis Pharmaceuticals by 33.0% during the third quarter. American Century Companies Inc. now owns 1,144,526 shares of the company’s stock worth $58,027,000 after buying an additional 284,266 shares during the period. First Trust Advisors LP boosted its position in shares of Ionis Pharmaceuticals by 40.2% during the third quarter. First Trust Advisors LP now owns 982,344 shares of the company’s stock worth $49,805,000 after buying an additional 281,733 shares during the period. Finally, Northern Trust Corp boosted its position in shares of Ionis Pharmaceuticals by 7.8% during the second quarter. Northern Trust Corp now owns 621,816 shares of the company’s stock worth $31,631,000 after buying an additional 44,750 shares during the period. Institutional investors and hedge funds own 91.59% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Ionis Pharmaceuticals, Inc. (IONS) Director Sells $160,650.00 in Stock” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.watchlistnews.com/ionis-pharmaceuticals-inc-ions-director-sells-160650-00-in-stock/1742693.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.